Unlike hematological malignancies, where specific antigens, such as CD19, CD20, or BCMA, are uniformly expressed and can be targeted with minimal risk of life-threatening off-target effects, solid tumors exhibit significant heterogeneity in surface antigen expression [22,23]. This evidence concerns the gene CD19 and hematologic disorder.